Cyto Pulse Sciences, Inc., the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Volunteers
2/22/2010 11:01:57 AM
GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval from the Swedish Medical Products Agency to conduct a phase I clinical trial evaluating an HIV/DNA vaccine in collaboration with the Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI). The vaccine will be delivered to healthy volunteers by ZetaJet®, a needle-free injection system (Bioject Medical Technologies Inc.) in combination with the intradermal electroporation system, Derma Vax™ (Cyto Pulse). The study will be sponsored by SMI and conducted at Södersjukhuset, KI, by Principal Investigator Bo Hejdeman, M.D., Ph.D. The multivalent HIV vaccine was developed jointly by SMI and KI.
comments powered by